Compare VBIX & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VBIX | PASG |
|---|---|---|
| Founded | N/A | 2017 |
| Country | Israel | United States |
| Employees | 21 | 27 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 26.0M |
| IPO Year | N/A | 2020 |
| Metric | VBIX | PASG |
|---|---|---|
| Price | $1.90 | $10.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $24.80 |
| AVG Volume (30 Days) | ★ 33.0K | 29.9K |
| Earning Date | 03-24-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.96 | $0.28 |
| 52 Week High | $6.31 | $20.00 |
| Indicator | VBIX | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 50.63 | 62.33 |
| Support Level | $1.51 | $10.24 |
| Resistance Level | $3.70 | $20.00 |
| Average True Range (ATR) | 0.22 | 1.14 |
| MACD | -0.02 | 0.47 |
| Stochastic Oscillator | 53.97 | 88.78 |
ViewBix Inc operates in the field of digital advertising. The company operates in single segment, the search segment that develops various technological software solutions, which perform automation, optimization, and monetization of internet campaigns, to obtain and route internet user traffic to its customers.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.